Research indicates that site-specific promoter hypermethylation of the WWOX gene is observed in 2 out of 15 (13%) primary pancreatic adenocarcinoma patients and in 2 out of 9 (22%) pancreatic cancer cell lines. The gene discussed is WWOX; the disease is pancreatic neoplasm.